Lee HA, Kim HY
Wang Y, Wang A, Alkhalidy H, et al
Top groups like the American Diabetes Association (ADA) and the American Association of Clinical Endocrinology (AACE) recommend these drugs as the first choice for people with type 2 diabetes and heart or kidney disease
#Pharma #GLP1 #ObesityTreatment #DrugDevelopment #HealthcareInnovation #EliLilly #NovoNordisk #PharmaceuticalIndustry To view or add a comment, sign in NEW DRUG APPROVAL ALERT The FDA has approved Foundayo (orforglipron), a new once-daily oral GLP-1 for chronic weight management in adults with obesity, or adults with overweight plus at least one weight-related condition
CJC 1295 without DAC at doses around 100 mcg in the Ionescu and Frohman 2006 study produced a GH spike followed by return to baseline within hours, resembling pulsatile behavior
Neonatal exposure to BPA, BDE-99, and PCB produces persistent changes in hepatic transcriptome associated with gut dysbiosis in adult mouse livers